Previous 10 | Next 10 |
EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Jefferies Healthcare Conference. Event: Jefferies Healthcare Conference Dates: June 8-10, 2022 Locat...
NuCana press release (NASDAQ:NCNA): Q4 GAAP EPS of -£0.26. As of December 31, 2021, NuCana had cash and cash equivalents of £60.3 million compared to £71.0 million at September 30, 2021 and £87.4 million as of December 31, 2020. Shares +1.23% AH. For further details see:...
Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer Extends Anticipated Cash Runway into 2025 EDINBURGH, United Kingd...
Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU NUC-3373 Did Not Generate Metabolites Associated with 5-FU Dose-Limiting Toxicities EDINBURGH, United Kingdom, M...
Gainers: Indonesia (NYSE:INDO) +60%. Tonix Pharmaceutical (NASDAQ:TNXP) +51%. Eos Energy Enterprises (NASDAQ:EOSE) +33%. Rimini Street (NASDAQ:RMNI) +30%. KLX Energy Services (NASDAQ:KLXE) +18%. DBV Technologies (NASDAQ:DBVT) +17%. Barrett Business Services (NASDAQ:BBSI) +16%. Ferroglobe (NAS...
Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%....
The ADRs of British biotech, NuCana (NASDAQ:NCNA) are trading ~55% lower in the pre-market Thursday after the company announced its decision to discontinue Phase 3 trial for Acelarin in biliary tract cancer. The study named NuTide:121 was designed to evaluate the potential of the co...
Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts and Dosing of First Patients in Phase 3 Colorectal Cancer Study Expected in ...
EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Event: Cowen’s 42nd Annual ...
Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data from Either Interim Analysis May Support an NDA Submission in the ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...